Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Recruiting 2Completed 2

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4Sarcoma 1

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 1Pathologic Complete Response 1Neoplasms 1Hemangiosarcoma 1

Interventions

Trastuzumab 628Paclitaxel 577Cyclophosphamide 555Docetaxel 485Capecitabine 402Letrozole 376Fulvestrant 327Doxorubicin 294Carboplatin 279Tamoxifen 275Anastrozole 243exemestane 228Radiotherapy 218Epirubicin 211Bevacizumab 196palbociclib 189pertuzumab 186Vinorelbine 167Lapatinib 167Gemcitabine 166pembrolizumab 162Surveys and Questionnaires 139Exercise 136Magnetic Resonance Spectroscopy 123Fluorouracil 119Blood Specimen Collection 118eribulin 117Albumin-Bound Paclitaxel 117Drug Therapy 111130-nm albumin-bound paclitaxel 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Breast Neoplasms × Lasofoxifene × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05696626 2026-04-21

ELAINEIII

LeonaBio

Phase 3 Recruiting
500 enrolled
Breast

Breast Neoplasms

NCT03781063 2026-01-28

Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Sermonix Pharmaceuticals Inc.

Phase 2 Completed
100 enrolled
Breast

Breast Neoplasms

NCT04432454 2025-02-13

ELAINEII

Sermonix Pharmaceuticals Inc.

Phase 2 Completed
29 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡